Our Pricing

Wegovy Weight Loss Injection UK: Clinical Guide

If you're searching for a wegovy weight loss injection uk provider with transparent pricing and genuine stock availability, Cured Pharmacy offers UK-licensed Wegovy pens from £79.00, dispensed following assessment by our UK-registered clinical team. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets MHRA standards for safety and authenticity.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a hormone your body naturally produces after eating [1]. By activating GLP-1 receptors in the brain, pancreas, and digestive system, semaglutide reduces appetite, slows gastric emptying, and improves blood sugar regulation—three mechanisms that work together to support sustained weight reduction.

In the STEP 1 clinical trial involving 1,961 adults with obesity, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 83.5% of Wegovy participants lost at least 5% of their baseline weight, and nearly half achieved reductions exceeding 15% [1]. These results represent the most substantial weight loss outcomes seen with any licensed pharmacological treatment in the UK to date.

Wegovy Dosing Schedule and Administration

Wegovy follows a structured dose-escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic efficacy [2]. Treatment begins at 0.25mg once weekly for four weeks, then increases progressively through 0.5mg, 1mg, and 1.7mg doses, reaching the maintenance dose of 2.4mg by week 17. Each dose level lasts four weeks, allowing your body to adapt gradually.

The pre-filled injection pens are administered subcutaneously—typically in the abdomen, thigh, or upper arm—on the same day each week, regardless of meal timing. Our clinical team provides detailed injection technique guidance during your consultation, and the pens feature hidden needles to reduce injection anxiety. If you miss a dose by fewer than five days, administer it as soon as you remember; if more than five days have passed, skip that dose and resume your regular schedule [2].

What to Expect During Dose Escalation

The gradual titration schedule exists specifically to reduce the incidence and severity of nausea, which affects approximately 44% of patients during initial treatment phases [1]. Most gastrointestinal symptoms diminish significantly after the first 8-12 weeks as your body adjusts. Eating smaller portions, avoiding high-fat meals, and staying well-hydrated can further minimise discomfort during the escalation period.

Wegovy Eligibility and Prescribing Criteria in the UK

Under MHRA licensing and NICE guidance, Wegovy is indicated for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. Your UK prescriber will calculate your BMI during the online consultation and review your medical history to confirm suitability.

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease [2]. It should be used with caution in those with a history of pancreatitis, diabetic retinopathy, or renal impairment. Pregnant or breastfeeding women cannot use Wegovy, and treatment should be discontinued at least two months before planned conception due to the medication's long half-life [2].

Common Side Effects and How to Manage Them

The most frequently reported adverse effects with Wegovy are gastrointestinal: nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These symptoms typically emerge during dose escalation and resolve or diminish substantially within 4-8 weeks. Eating smaller, more frequent meals and avoiding rich or spicy foods can help manage these effects.

Less common but notable side effects include injection site reactions (redness, itching), fatigue, dizziness, and abdominal discomfort. Approximately 7% of trial participants discontinued treatment due to adverse events, most commonly gastrointestinal in nature [1]. Serious but rare risks include pancreatitis (characterised by severe abdominal pain radiating to the back), gallbladder disease, and hypoglycaemia in patients using concurrent diabetes medications. If you experience persistent vomiting, severe abdominal pain, or visual changes, contact a healthcare professional immediately.

When to Contact Your Prescriber

Whilst mild nausea is expected and manageable, you should reach out to your prescriber if side effects interfere significantly with daily activities, if you're unable to maintain adequate hydration due to vomiting, or if symptoms worsen rather than improve after the first month. Your prescriber may recommend slowing the dose escalation or implementing additional supportive measures to improve tolerability.

Wegovy vs Saxenda vs Mounjaro: Comparing GLP-1 Treatments

Wegovy, Saxenda, and Mounjaro represent three distinct generations of incretin-based weight loss therapies available through UK pharmacies. Saxenda contains liraglutide, an earlier GLP-1 agonist requiring daily injections and typically producing 5-8% average weight loss over one year [4]. Wegovy's once-weekly semaglutide formulation offers superior convenience and efficacy, with clinical trials demonstrating nearly double the weight reduction compared to liraglutide [1][4].

Mounjaro (tirzepatide) is the newest option, combining GLP-1 receptor activation with glucose-dependent insulinotropic polypeptide (GIP) agonism—a dual mechanism that has produced average weight reductions exceeding 20% in clinical trials [5]. Whilst Mounjaro shows the highest efficacy in head-to-head comparisons, individual response varies, and factors including injection frequency preference, side effect profile, cost, and medical history all influence which treatment your prescriber recommends. All three medications require prescription-only access following clinical assessment by a UK-registered prescriber.

Ordering Wegovy from Cured Pharmacy: The Process

Our streamlined consultation process takes under three minutes and can be completed entirely online at your convenience. You'll answer questions about your weight history, current medications, medical conditions, and treatment goals. A UK-registered prescriber reviews your assessment—typically within 24 hours—and if Wegovy is clinically appropriate, your prescription is issued and forwarded to our dispensary.

We dispatch all orders in 100% discreet packaging via tracked courier, with most UK addresses receiving delivery within 2-3 working days. Our pricing is transparent and displayed upfront: Wegovy starts from £79.00 depending on your prescribed dose, with no hidden consultation fees or subscription commitments. As a GPhC-registered pharmacy (9012511), we dispense only genuine UK-licensed medications sourced through authorised wholesalers. If you have questions at any stage, our pharmacy team is available on (+44) 116 4646009 during business hours.

Ongoing Support and Prescription Renewals

Weight loss treatment with Wegovy is most effective when sustained over 12-18 months, combined with dietary modification and increased physical activity [3]. Our clinical team can arrange prescription renewals following brief follow-up consultations to assess your progress, tolerability, and any dose adjustments needed. NICE recommends discontinuing treatment if you haven't achieved at least 5% weight loss after 12 weeks at the maintenance dose, as continued use is unlikely to produce meaningful benefit [3].

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. Retrieved from https://www.nice.org.uk/guidance/ta875
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.